Top

Cancer Chemotherapy and Pharmacology

Published in:

01-03-2018 | Original Article

Role of TPMT and ITPA variants in mercaptopurine disposition

Authors: Tina Gerbek, Maria Ebbesen, Jacob Nersting, Thomas L. Frandsen, Malin Lindqvist Appell, Kjeld Schmiegelow

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2018

Abstract

Purpose

To explore the levels of thioguanine incorporated into DNA (DNA-TG), and erythrocyte levels of 6-thioguanine nucleotides (Ery-TGN) and methylated metabolites (Ery-MeMP) during 6-mercaptopurine (6MP)/Methotrexate (MTX) therapy of childhood acute lymphoblastic leukemia (ALL) and the relation to inosine triphosphatase (ITPA) and thiopurine methyltransferase (TPMT) gene variants.

Methods

Blood samples were drawn during 6MP/MTX maintenance therapy from 132 children treated for ALL at Rigshospitalet, Copenhagen. The samples were analysed for thiopurine metabolites and compared to TPMT (rs1800460 and rs1142345) and ITPA (rs1127354) genotypes.

Results

Median DNA-TG (mDNA-TG) levels were higher in TPMT and ITPA low-activity patients as compared to wildtype patients (TPMT^LA 549 vs. 364 fmol/µg DNA, p = 0.007, ITPA^LA 465 vs. 387 fmol/µg DNA, p = 0.04). mDNA-TG levels were positively correlated to median Ery-TGN (mEry-TGN)(r_s = 0.37, p = 0.001), but plateaued at higher mEry-TGN levels. DNA-TG indices (mDNA-TG/mEry-TGN) were 42% higher in TPMT^WT patients as compared to TPMT^LA patients but no difference in DNA-TG indices was observed between ITPA^WT and ITPA^LA patients (median 1.7 vs. 1.6 fmol/µg DNA/ nmol/mmol Hb, p = 0.81). DNA-TG indices increased with median Ery-MeMP (mEry-MeMP) levels (r_s = 0.25, p = 0.001).

Conclusions

TPMT and ITPA genotypes significantly influence the metabolism of 6MP. DNA-TG may prove to be a more relevant pharmacokinetic parameter for monitoring 6MP treatment intensity than cytosolic metabolites. Prospective trials are needed to evaluate the usefulness of DNA-TGN for individual dose adjustments in childhood ALL maintenance therapy.

Chiengthong K, Ittiwut C, Muensri S, Sophonphan J, Sosothikul D, Seksan P, et al (2016) NUDT15 c.415C > T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. Haematologica 101(1):e24–e26CrossRefPubMedPubMedCentral

Liang DC, Yang CP, Liu HC, Jaing TH, Chen SH, Hung IJ et al (2016) NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J 16(6):536–539CrossRefPubMed

Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X et al (2016) NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 48(4):367–373CrossRefPubMedPubMedCentral

Moriyama T, Nishii R, Lin TN, Kihira K, Toyoda H, Jacob N et al (2017) The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics 27(6):236–239CrossRefPubMed

Suzuki H, Fukushima H, Suzuki R, Hosaka S, Yamaki Y, Kobayashi C et al (2016) Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age. J Hum Genet 61(9):797–801CrossRefPubMed

Tanaka Y, Kato M, Hasegawa D, Urayama KY, Nakadate H, Kondoh K et al (2015) Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br J Haematol 171(1):109 – 15CrossRefPubMed

Yang JJ, Landier W, Yang W, Liu C, Hageman L, Cheng C et al (2015) Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 33(11):1235–1242CrossRefPubMedPubMedCentral

Bierau J, Lindhout M, Bakker JA (2007) Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 8(9):1221–1228CrossRefPubMed

Kim H, Kang HJ, Kim HJ, Jang MK, Kim NH, Oh Y et al (2012) Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS One 7(9):e45558CrossRefPubMedPubMedCentral

10.

Stocco G, Crews KR, Evans WE (2010) Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin Drug Saf 9(1):23–37CrossRefPubMed

11.

Stocco G, Franca R, Londero M, Decorti G (2013) ITPA genetic polymorphism is possibly associated with survival rate in Korean children with acute lymphoblastic leukemia. Pharmacogenomics 14(3):237–238CrossRefPubMed

12.

Tanaka Y, Manabe A, Nakadate H, Kondoh K, Nakamura K, Koh K et al (2012) The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children. Leuk Res 36(5):560–564CrossRefPubMed

13.

Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M et al (1996) Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273(5278):1109–1111CrossRefPubMed

14.

Karran P, Attard N (2008) Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 8(1):24–36CrossRefPubMed

15.

Lilleyman JS, Lennard L (1994) Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 343(8907):1188–1190CrossRefPubMed

16.

Hedeland RL, Hvidt K, Nersting J, Rosthoj S, Dalhoff K, Lausen B et al (2010) DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Cancer Chemother Pharmacol 66(3):485–491CrossRefPubMed

17.

Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE (1995) Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol 47(6):1141–1147PubMed

18.

Marsh S, King CR, Ahluwalia R, McLeod HL (2004) Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet 49(10):579–581CrossRefPubMed

19.

Mohandas T, Sparkes RS, Passage MB, Sparkes MC, Miles JH, Kaback MM (1980) Regional mapping of ADA and ITP on human chromosome 20: cytogenetic and somatic cell studies in an X/20 translocation. Cytogenet Cell Genet 26(1):28–35CrossRefPubMed

20.

Azimi F, Mortazavi Y, Alavi S, Khalili M, Ramazani A (2015 Oct) Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects. Leuk Res 39(10):1048–1054CrossRefPubMed

21.

Marinaki AM, Duley JA, Arenas M, Ansari A, Sumi S, Lewis CM et al (2004) Mutation in the ITPA gene predicts intolerance to azathioprine. Nucleosides Nucleotides Nucleic Acids 23(8–9):1393–1397CrossRefPubMed

22.

Stocco G, Franca R, Verzegnassi F, Londero M, Rabusin M, Decorti G (2012) Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia. Front Genet 3:309PubMed

23.

Toft N, Schmiegelow K, Klausen TW, Birgens H (2012) Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998–2008. Br J Haematol 157(1):97–104CrossRefPubMed

24.

Toft N, Birgens H, Abrahamsson J, Bernell P, Griskevicius L, Hallbook H et al (2013) Risk group assignment differs for children and adults 1–45 year with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol 90(5):404–412CrossRefPubMed

25.

Hindorf U, Lindqvist M, Peterson C, Soderkvist P, Strom M, Hjortswang H et al (2006 Oct) Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 55(10):1423–1431CrossRefPubMedPubMedCentral

26.

Jacobsen JH, Schmiegelow K, Nersting J (2012) Liquid chromatography-tandem mass spectrometry quantification of 6-thioguanine in DNA using endogenous guanine as internal standard. J Chromatogr B Analyt Technol Biomed Life Sci 881–882:115–118CrossRefPubMed

27.

Wang L, Weinshilboum R (2006) Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 25(11):1629–1638CrossRefPubMed

28.

Davidsen ML, Dalhoff K, Schmiegelow K (2008) Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 30(11):831–849CrossRefPubMed

29.

Farfan MJ, Salas C, Canales C, Silva F, Villarroel M, Kopp K et al. Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia. BMC Cancer 2014 Apr 28;14:299

30.

Fotoohi AK, Coulthard SA, Albertioni F (2010) Thiopurines: factors influencing toxicity and response. Biochem Pharmacol 79(9):1211–1220CrossRefPubMed

31.

Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW et al (2013) Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 93(4):324–325CrossRefPubMedPubMedCentral

32.

Schmiegelow K, Pulczynska MK (1990) Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts? Am J Pediatr Hematol Oncol 12(4):462–467CrossRefPubMed

33.

Schmiegelow K, Nersting J, Nielsen SN, Heyman M, Wesenberg F, Kristinsson J et al (2016 Dec) Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts? Pediatr Blood Cancer 63(12):2104–2111CrossRefPubMed

34.

Schmiegelow K, Pulczynska MK (1990 Jan) White-cell counts in childhood acute lymphoblastic leukemia. Eur J Haematol 44(1):72–74CrossRefPubMed

35.

Van den Bossche J, Devreese K, Malfait R, Van d V, Wauters A, Neeis H et al (2002 Jan) Reference intervals for a complete blood count determined on different automated haematology analysers: Abx Pentra 120 Retic, Coulter Gen-S, Sysmex SE 9500, Abbott Cell Dyn 4000 and Bayer Advia 120. Clin Chem Lab Med 40(1):69–73CrossRefPubMed

36.

Ebbesen MS, Nersting J, Jacobsen JH, Frandsen TL, Vettenranta K, Abramsson J et al (2013 Jun) Incorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukemia—the influence of thiopurine methyltransferase genotypes. J Clin Pharmacol 53(6):670–674CrossRefPubMed

37.

Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM et al (2004) Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14(3):181–187CrossRefPubMed

38.

Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, van Kampen AH, Curvers WL et al (2006) Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 4(1):44–49CrossRefPubMed

39.

Adam de BT, Fakhoury M, Medard Y, Azougagh S, Zhang D, Yakouben K et al (2011) Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol 71(4):575–584CrossRef

40.

Hareedy MS, El Desoky ES, Woillard JB, Thabet RH, Ali AM, Marquet P et al (2015) Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics 16(10):1119–1134CrossRefPubMed

41.

Wan Rosalina WR, Teh LK, Mohamad N, Nasir A, Yusoff R, Baba AA et al (2012) Polymorphism of ITPA 94C > A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine. J Clin Pharm Ther 37(2):237–241CrossRefPubMed

42.

Smid A, Karas-Kuzelicki N, Milek M, Jazbec J, Mlinaric-Rascan I (2014) Association of ITPA genotype with event-free survival and relapse rates in children with acute lymphoblastic leukemia undergoing maintenance therapy. PLoS One 9(10):e109551CrossRefPubMedPubMedCentral

43.

Duley JA, Florin TH (2005 Oct) Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther Drug Monit 27(5):647–654CrossRefPubMed

44.

Bergan S, Bentdal O, Sodal G, Brun A, Rugstad HE, Stokke O (1997 Oct) Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts. Ther Drug Monit 19(5):502–509CrossRefPubMed

45.

Lancaster DL, Lennard L, Rowland K, Vora AJ, Lilleyman JS (1998 Jul) Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations. Br J Haematol 102(2):439–443CrossRefPubMed

Title: Role of TPMT and ITPA variants in mercaptopurine disposition
Authors: Tina Gerbek
Maria Ebbesen
Jacob Nersting
Thomas L. Frandsen
Malin Lindqvist Appell
Kjeld Schmiegelow
Publication date: 01-03-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3525-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202)

A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer

Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study

Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML

A note on improved statistical approaches to account for pseudoprogression

2-Deoxy-d-glucose enhances TRAIL-induced apoptosis in human gastric cancer cells through downregulating JNK-mediated cytoprotective autophagy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer